Every material Form 8-K Neurocrine Biosciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neurocrine Biosciences amended the employment agreement with Eiry W. Roberts, M.D., its former Chief Medical Officer, on November 21, 2025. The amendment extends her employment term by 12 months, to December 31, 2026. Sanjay Keswani, M.D. has served as Chief Medical Officer since June 2, 2025, so the change does not alter that role.
Amendment dated November 21, 2025 extends the term of employment by an additional 12 months, expiring December 31, 2026.
Sanjay Keswani, M.D. succeeded Dr. Roberts as Chief Medical Officer effective June 2, 2025.
Under the prior agreement, Dr. Roberts served as Strategic Advisor through December 31, 2025.
Full text of the amendment is filed as Exhibit 10.1.
Neurocrine Biosciences reported third-quarter 2025 results, with total net product sales of $790 million, up 28% from a year earlier, and GAAP diluted earnings per share of $2.04 versus $1.24. The company reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.55 billion and updated its R&D and SG&A expense ranges.
Total net product sales were $790 million for the quarter, up 28% year over year and 16% sequentially.
GAAP net income was $210 million ($2.04 per diluted share), compared with $130 million ($1.24) in the third quarter of 2024.
CRENESSITY net product sales were $98 million in the quarter, with 540 new patient enrollment start forms.
Full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.55 billion was reaffirmed; GAAP R&D guidance is $1.0 billion to $1.02 billion.
Neurocrine Biosciences reported second-quarter 2025 net product sales of $682 million, up 17% year over year, and GAAP diluted earnings per share of $1.06 versus $0.63 a year earlier. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion, lowering the top of the range, and said a Phase 3 study of valbenazine in schizophrenia did not meet its primary endpoint.
Q2 2025 net product sales were $682 million: INGREZZA $624.4 million and CRENESSITY $53.2 million
GAAP net income was $107.5 million ($1.06 per diluted share) versus $65.0 million ($0.63) in Q2 2024; non-GAAP EPS was $1.65 versus $1.63
INGREZZA 2025 net product sales guidance narrowed to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion
Company repurchased $18 million of stock in Q2 2025 and had $332 million remaining under its $500 million program as of June 30, 2025
Neurocrine Biosciences said Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will stay on as Strategic Advisor to the CEO through December 31, 2025 under an amended employment agreement with a $731,400 base salary.
Sanjay Keswani, M.D. succeeds Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025
Dr. Roberts becomes Strategic Advisor to the CEO through December 31, 2025, with a $731,400 annual base salary
Dr. Roberts's target bonus is 60% of base pay for calendar year 2025; severance and outstanding equity awards carry over
At its May 21, 2025 annual meeting, Neurocrine Biosciences stockholders approved the 2025 Equity Incentive Plan and an amended and restated 2018 Employee Stock Purchase Plan, elected four Class II directors, and approved the advisory vote on executive compensation. Stockholders also ratified Ernst & Young LLP as the independent auditor for fiscal 2025. The filing reports the vote results, which are routine annual-meeting outcomes.
The 2025 Equity Incentive Plan was approved with 72,648,862 votes for and 12,884,104 against.
Four Class II directors were elected to three-year terms expiring at the 2028 annual meeting, including Richard F. Pops with 72,919,088 votes for.
Of 98,938,234 shares entitled to vote, 90,434,193 were present in person or by proxy.
Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 85,019,349 votes for.
Neurocrine Biosciences reported first-quarter 2025 total revenues of $572.6 million, up from $515.3 million a year earlier, while GAAP diluted earnings per share fell to $0.08 from $0.42. The company reaffirmed its full-year 2025 INGREZZA net sales guidance of $2.5 billion to $2.6 billion, but higher R&D spending and a $30.6 million unrealized loss on equity investments reduced profit.
INGREZZA first-quarter net product sales were $545.2 million, compared with $506.0 million a year earlier; CRENESSITY sales were $14.5 million.
GAAP net income was $7.9 million, versus $43.4 million in Q1 2024; non-GAAP net income was $71.5 million, versus $124.8 million.
Q1 2025 R&D expense includes $45 million of development milestones, mainly tied to starting the osavampator Phase 3 program in major depressive disorder.
Cash, cash equivalents and marketable securities totaled $1,758.8 million at March 31, 2025, and $150 million of a $500 million buyback had been repurchased by that date.
Neurocrine Biosciences said Sanjay Keswani, M.D., will succeed Eiry W. Roberts, M.D., as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will remain with the company in a strategic advisory role. The change replaces a long-serving clinical leader with an executive who has more than 20 years of pharmaceutical industry experience.
Sanjay Keswani, M.D., agreed on April 2, 2025 to become Chief Medical Officer, effective June 2, 2025
Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years
Dr. Roberts previously announced her retirement in July 2023 and will stay on in a strategic advisory role
Dr. Keswani was previously President and CEO of ImmunoBrain and held R&D roles at Hoffmann-La Roche and Bristol-Myers Squibb
Neurocrine Biosciences reported fourth-quarter 2024 total revenues of $627.7 million, up from $515.2 million a year earlier, driven by INGREZZA net product sales of $615 million. GAAP net income fell to $103.1 million, or $1.00 per diluted share, from $147.7 million, or $1.44, as operating expenses rose, while non-GAAP diluted EPS rose to $1.69 from $1.54. The company also issued full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.6 billion.
Q4 2024 total revenues $627.7 million vs. $515.2 million in Q4 2023; full-year 2024 total revenues $2,355.3 million vs. $1,887.1 million
Q4 2024 GAAP diluted EPS $1.00 vs. $1.44; non-GAAP diluted EPS $1.69 vs. $1.54, with the company citing $28 million of higher stock-based compensation tied to CRENESSITY approval and the CEO retirement charge
CRENESSITY fourth-quarter 2024 net product sales were $2 million, reflecting initial pharmacy orders after FDA approval in December 2024
Full-year 2025 guidance: INGREZZA net product sales of $2.5 billion to $2.6 billion; non-GAAP R&D of $890 million to $940 million and non-GAAP SG&A of $955 million to $975 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neurocrine Biosciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →